Dr. Clay Siegall And Seattle Genetics:Creating Groundbreaking Cancer Treatments

When Clay Siegall was an undergraduate at the University of Maryland working on his bachelor’s degree in Zoology, he saw how receiving cancer treatment devastated the life of one of his family members. He was so moved, he went on to graduate from George Washington University with a doctorate in genetics and he has spent more than 20 years researching and producing effective ways to treat cancer while improving the quality of life for the patients. Today Dr. Clay Siegall is the founder and CEO of one of the leading developers of targeted cancer treatments, Seattle Genetics.

Founded in 1998, Seattle Genetics is a biotechnology company that has created one of the most effective targeted cancer treatment drugs and the first to receive FDA approval. That drug, ADCETRIS, is now used in over 60 countries to treat cancer. Dr. Siegall has also secured important partnerships with Bayer, Pfizer, Genentech and a number of other companies to market ADCETRIS all over the world. Not only has ADCETRIS been a great success, Seattle Genetics also has a rich product pipeline that has in excess of 20 new cancer treatments that show great potential.

Since earning his Ph.D., Dr. Clay Siegall has shown his commitment to and passion for cancer research by working with a number of the field’s leading companies. They include the National Institutes of Health, the National Cancer Institute and Bristol-Myers Squibb Pharmaceutical Research Institute. A relentless fundraiser, Dr. Siegall has reached out to both public and private sources to garner Seattle Genetics over $1.2 billion in funds since their initial public offering in 2001. That has helped the company recruit, train and retain some of the most talented people in the industry.

Dr. Clay Siegall is an individual with great vision. Not only has he been able to assemble a top-notch staff and create a great drug development pipeline at Seattle Genetics, he also holds 15 patents. He has also written articles on cancer for over 70 publications. His work with Seattle Genetics has also led to him being chosen 2012 Entrepreneur of the Year by Ernst & Young.